PTJ
IPSC icon

Paul Tudor Jones’s Century Therapeutics IPSC Stock Holding History

Paul Tudor Jones’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7,000
Closed -$205K – 2624
2021
Q2 		$205K Buy
+7,000
New +$178K ﹤0.01% 1489

Other funds holding IPSC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Paul Tudor Jones's IPSC Position: Q3 2021 in Review

Paul Tudor Jones sold out of Century Therapeutics (IPSC) in Q3 2021, closing a stake of 7,000 shares — an estimated $205K sold.

Paul Tudor Jones first reported a position in IPSC in Q2 2021 and held it in 1 quarter. The position peaked at $205K in Q2 2021. 49 funds tracked by Wall St. Rank hold IPSC as of Q3 2021.

  • Paul Tudor Jones reported no remaining Century Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Paul Tudor Jones sold 7,000 Century Therapeutics shares in Q3 2021, an estimated $205K.
  • Paul Tudor Jones first reported a position in Century Therapeutics in Q2 2021 and held it in 1 quarter.
  • Paul Tudor Jones's Century Therapeutics position peaked at $205K in Q2 2021.
  • 49 funds tracked by Wall St. Rank held Century Therapeutics as of Q3 2021.

Based on Tudor Investment Corp's 13F filing for Q3 2021, filed 15 Nov 2021.